Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy

To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy

Inclusion Criteria:

• Diagnosis of migraine headache according to International Headache Society criteria and migraine headaches for at least 1 year
• Eletriptan naive
• Previously treated with rizatriptan and failed to achieve a satisfactory response within the past 12 months

Exclusion Criteria:

• Non-migraine headaches on average more than 6 days per month or have less than 24 hours of freedom from headache between migraine attacks
• Migraine attacks that are atypical or chronic daily headaches
• A history of migraine with prolonged aura, familial hemiplegic migraine, basilar migraine, migrainous infarction, migraine aura without headache, migraine with acute onset aura